Cargando…
Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers
The advent of molecular profiling has revolutionized the treatment of lung cancer by comprehensively delineating the genomic landscape of the epidermal growth factor receptor (EGFR) gene. Drug resistance caused by EGFR mutations and genetic polymorphisms of drug metabolizing enzymes and transporters...
Autores principales: | Kolesar, Jill, Peh, Spencer, Thomas, Levin, Baburaj, Gayathri, Mukherjee, Nayonika, Kantamneni, Raveena, Lewis, Shirley, Pai, Ananth, Udupa, Karthik S., Kumar AN, Naveena, Rangnekar, Vivek M., Rao, Mahadev |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867675/ https://www.ncbi.nlm.nih.gov/pubmed/35209919 http://dx.doi.org/10.1186/s12943-022-01534-8 |
Ejemplares similares
-
Cannabinoids as an Alternative Option for Conventional Analgesics in Cancer Pain Management: A Pharmacogenomics Perspective
por: Jose, Anmi, et al.
Publicado: (2020) -
Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology
por: Mathai, Roshni Ann, et al.
Publicado: (2019) -
Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies
por: Baburaj, Gayathri, et al.
Publicado: (2021) -
Pharmacogenomics in Palliative Medicine
por: Rao, Mahadev
Publicado: (2019) -
Quality of Sleep in Patients with Cancer: A Cross-sectional Observational Study
por: Pai, Ananth, et al.
Publicado: (2020)